Anti-nausea drug could help treat sleep apnea

June 6, 2017
Illustration of obstruction of ventilation. Credit: Habib M’henni / public domain

An old pharmaceutical product may be a new treatment for obstructive sleep apnea, according to new research presented today by University of Illinois at Chicago and Northwestern University scientists at the SLEEP 2017 annual meeting in Boston.

David Carley, professor of biobehavioral health sciences, medicine and bioengineering at UIC; Phyllis Zee, professor of neurology at Northwestern University; and their colleagues have discovered that dronabinol, approved by the U.S. Food and Drug Administration more than 25 years ago to treat nausea and vomiting in chemotherapy patients, can help people who suffer from sleep apnea.

"At the present time there are no approved treatments for sleep apnea, and there remains an important unmet need for fully effective and acceptable treatments of the disorder," said Carley.

Obstructive sleep apnea is a condition where breathing is briefly but repeatedly interrupted during sleep. It occurs when the throat muscles fail to keep the airway open during sleep, despite efforts to breathe. An estimated 22 million Americans suffer from the disorder, with 80 percent of the cases of moderate and severe obstructive sleep apnea undiagnosed.

Sleep related breathing disorders, especially obstructive sleep apnea, pose significant health problems. Individuals suffering from sleep apnea have an increased risk for , stroke, and type 2 diabetes.

In a previous study, Carley found dronabinol, a cannabinoid agonist, held significant potential for treating sleep apnea.

Expanding on this research, Carley and Zee received a federal grant to initiate the Pharmacotherapy of Apnea by Cannabimimetic Enhancement (PACE) study. It is the largest National Institutes of Health-sponsored randomized controlled trial of any existing drug treatment for obstructive sleep apnea syndrome to date.

Adult patients were divided into three groups. One group was given a low dose of the drug, a second group received a higher dose, and the third, a placebo. Participants received the drug once daily before bed for six weeks.

"In comparison to placebo, six weeks of treatment by the highest dose of dronabinol (10 milligrams) was associated with a lower frequency of apneas or hypopneas during sleep, decreased subjective sleepiness, and greater overall treatment satisfaction," Carley said. "Neither the amount of sleep nor objective sleepiness improved."

UIC has licensed intellectual property related to the experimental drug used in the study to the pharmaceutical company RespireRx.

Researchers have attempted to identify drugs to treat sleep apnea for nearly 35 years, but to no avail, Carley said.

"By providing a path toward the first viable obstructive sleep apnea drug, our studies could have a major impact on clinical practice," he said. "However, expanded and pivotal clinical trials must still be conducted to fully establish the best approach to cannabinoid therapy in ."

Explore further: Can cannabinoid drug used for nausea in chemotherapy relieve sleep apnea?

Related Stories

Can cannabinoid drug used for nausea in chemotherapy relieve sleep apnea?

June 21, 2012
(Medical Xpress) -- No drug treatments exist to treat sleep apnea, a disorder that affects more than 18 million Americans. Researchers at the University of Illinois at Chicago College of Nursing are working to change that. ...

Mild-to-moderate obstructive sleep apnea is associated with hypertension, diabetes

June 5, 2017
Preliminary data from two studies suggest that mild-to-moderate obstructive sleep apnea is associated with an increased risk of developing hypertension and diabetes.

Babies born to mothers with sleep apnea have higher risk of adverse neonatal outcomes

June 4, 2017
A new study is the first to demonstrate a higher risk of congenital anomalies and resuscitation at birth in newborns of mothers who have obstructive sleep apnea.

Study finds no link between sleep apnea and joint pain

August 1, 2016
Consistent with previous reports, poor sleep quality was linked with joint pain in a recent Arthritis Care & Research study of the general population, but the study found no association between obstructive sleep apnea and ...

Sleep apnea treatment may reverse unhealthy brain changes

September 15, 2015
(HealthDay)—Sleep apnea treatment may reverse changes in brain stem activity associated with increased risk of heart disease, a new study suggests.

Study finds that CPAP therapy reduces acid reflux in people with sleep apnea

October 3, 2016
A new study suggests that CPAP therapy may help improve the symptoms of nocturnal gastroesophageal reflux in patients with obstructive sleep apnea.

Recommended for you

Synthetic cannabinoid reduces sleep apnea

November 29, 2017
A synthetic version of a molecule found in the cannabis plant was safe and effective in treating obstructive sleep apnea in the first large, multi-site study of a drug for the sleep disorder funded by the National Institutes ...

Sleeping through the snoring: Researchers identify neurons that rouse the brain to breathe

November 2, 2017
A common and potentially serious sleep disorder, obstructive sleep apnea affects at least one quarter of U.S. adults and is linked to increased risk of diabetes, obesity and cardiovascular disease. In a paper published today ...

Remede system approved for sleep apnea

October 9, 2017
(HealthDay)—The Remede sleep system, an implanted device that treats central sleep apnea by activating a nerve that sends signals to the diaphragm to stimulate breathing, has been approved by the U.S. Food and Drug Administration.

Inflammation may precede sleep apnea, could be treatment target

September 1, 2017
Inflammation is traditionally thought of as a symptom of sleep apnea, but it might actually precede the disorder, potentially opening the door for new ways to treat and predict sleep apnea, according to researchers.

More evidence: Untreated sleep apnea shown to raise metabolic and cardiovascular stress

August 31, 2017
Sleep apnea, left untreated for even a few days, can increase blood sugar and fat levels, stress hormones and blood pressure, according to a new study of sleeping subjects. A report of the study's findings, published in the ...

Sleep patterns contribute to racial differences in disease risk

August 18, 2017
Poor sleep patterns could explain, in part, the differences in the risk of cardiometabolic disease between African-Americans and European-Americans, according to a new study published in Proceedings of the National Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.